Iovance Biotherapeutics, Inc.

What they do

Iovance develops and commercializes individualized TIL cell therapies for solid tumor cancers, manufacturing each patient's polyclonal T cells into the billions using centralized, proprietary processes. Its two commercial products are Amtagvi (lifileucel), a one-time TIL therapy for previously treated advanced melanoma, and Proleukin (aldesleukin), an IL-2 product used in the Amtagvi regimen and other applications. Amtagvi is approved in the U.S., Canada, and Australia, and is administered at authorized treatment centers (ATCs) as part of a regimen including lymphodepletion and a short course of Proleukin.

Revenue drivers

• U.S. Amtagvi (lifileucel) — The dominant revenue source: approximately $91 million in Q2 2026, up 40% from Q4 2025, driven by demand across a growing U.S. ATC network.
• Global Proleukin (aldesleukin) — Approximately $9 million in Q2 2026; used in the Amtagvi treatment regimen and other applications, and management expects growth during the remainder of 2026.
• International Amtagvi — Approved in Canada and Australia (TGA authorization June 2026), with Australian ATCs progressing through authorization and national reimbursement discussions; no international revenue figures were disclosed.

Recent performance

Second quarter 2026 total product revenue was a record ~$99.3 million, up 66% from ~$60 million in Q2 2025 and 39% from ~$71 million in Q1 2026. U.S. Amtagvi revenue was ~$91 million and global Proleukin revenue was ~$9 million. Gross margin was 56%, which the company attributed to higher Amtagvi sales volume, cost optimization, and maturing internal manufacturing efficiencies. R&D expenses decreased ~6% versus Q1 2026, the fourth straight quarter of improvement. Full year 2025 revenue was $263.5 million against a net loss of $391.0 million, and operating cash flow was negative $302.4 million.

Strategy

The stated top priority is driving commercial success of Amtagvi in previously treated advanced melanoma by educating and training healthcare professionals, supporting and onboarding ATCs, collaborating with payors on reimbursement, and improving launch and manufacturing execution. The company is expanding globally: it won Australian approval in June 2026, resubmitted its UK MAA in July 2026 under expedited MHRA review, and is working with the EMA to resubmit an EU centralized MAA in 2026 or 2027. It is running two registrational trials in frontline advanced melanoma and previously treated advanced NSCLC, and has commenced a registrational trial in advanced UPS and DDLPS (SARATOGA), where it received FDA Fast Track designation. Management is also pursuing manufacturing and operating efficiencies to support growth and progress toward profitability.

Risks

• History of losses and need for financing — Iovance has incurred operating losses every year shown, including a $391.0 million net loss in 2025, and states it may need additional financing that could dilute stockholders or restrict operations.
• Complex manufacturing — Manufacturing TIL therapies is complex and the company warns that process development, quality control, or scaling difficulties could delay or stop supply or prevent a commercially viable cost structure.
• Regulatory and approval timing — Amtagvi's U.S. approval is accelerated, and pending approvals in the UK and Switzerland and a resubmitted EU MAA depend on regulatory decisions; the company withdrew its initial EU MAA in July 2025.
• Dependence on continued Amtagvi demand and reimbursement — Results depend on adoption across ATCs and payor reimbursement, and the company is reviewing its previously issued FY26 revenue guidance of $350 million to $370 million.

Outlook

Management is reviewing its previously issued full year 2026 total revenue guidance of $350 million to $370 million based on strong second-quarter sales and demand trends, with an update planned during the third quarter. It expects gross margin improvements to continue, excluding occasional one-time items, and expects global Proleukin revenue to grow during the remainder of 2026. The company expects at least 110 active ATCs by the end of 2026 and potential UK approval later in 2026, with Switzerland pending in 2027.